Search

Apomorphine

[A203618] Apomorphine has also been investigated as an emetic, a sedative, a treatment for alcoholism, and a treatment of other movement disorders. … Apomorphine is a non-ergoline dopamine D2 agonist indicated to treat hypomobility associated with Parkinson's. It was first synthesized in 1845 and first used in Parkinson's disease in 1884.

Cerliponase alfa

Cerliponase alfa is a hydrolytic lysosomal N-terminal tripeptidyl peptidase-1 (TPP1). … [L51329] CLN2 is a predominantly pediatric-onset neurodegenerative disease caused by a deficiency in the lysosomal enzyme TPP1, leading to progressive impairment in motor and cognitive function.

Iron protein succinylate

Alpelisib

It works by selectively inhibiting class I PI3K p110α [A179203], which is the catalytic subunit of PI3K, a lipid kinase that plays a role in various biological processes, including proliferation, survival … Alpelisib was designed to target this enzyme that appears to be mutated at a rate of nearly 30% in human cancers, leading to hyperactivation.

Ipecac

Ipecac is obtained from the plant _Cephaelis ipecacuanha_ and contains a number of emetic alkaloids including emetine and cephaeline. … use to cause vomiting in poisoning.

Tipiracil

Tipiracil is a thymidine phosphorylase inhibitor. It is used in combination with trifluridine, in a ratio of 1:0.5, to form TAS-102. … The main function of Tipiracil in TAS-102 is to increase trifluridine bioavailability by inhibiting its catabolism.

Trastuzumab deruxtecan

Trastuzumab deruxtecan is a HER2-directed antibody attached to a topoisomerase inhibitor that is approved for use in certain types of treatment-resistant HER2-positive cancers. … [A188988] Trastuzumab deruxtecan was developed by Daiichi Sankyo in collaboration with AstraZeneca and was first approved by the FDA in 2019.[L10842]

Eflornithine

a 68% reduction in the risk of death were observed. … This approval is based on positive results obtained from a multi-site, single-arm, externally controlled study of children with high-risk neuroblastoma, where a 52% reduction in the risk of relapse and

Icosapent ethyl

Icosapent ethyl or ethyl eicosapentaenoic acid is a synthetic derivative of the omega-3 fatty acid eicosapentaenoic acid (EPA). … FDA approved on July 26, 2012.

Lerodalcibep

[L54738] PCSK9 is a protein that binds to and promotes the degradation of low-density lipoprotein receptors (LDLRs), which are expressed on hepatocytes regulates circulating LDL levels. … Lerodalcibep is a recombinant fusion protein that binds to and inhibits proprotein convertase subtilisin kexin type 9 (PCSK9).